Year 2022 / Volume 114 / Number 7
Letter
Mesalazine induced interstitial pneumonitis in the COVID era

429-430

DOI: 10.17235/reed.2022.8635/2021

Ana Aparicio Serrano, Elma Gallego Jiménez, Javier Castro Rodríguez, Pilar Soto Escribano, Eva Iglesias Flores, Sandra Marín Pedrosa, José Manuel Benítez,

Abstract
Mesalazine is the most widely used aminosalicylate for induction and maintenance of remission in patients with mild-to-moderate ulcerative colitis (UC). Drug-induced hypersensitivity pneumonitis is considered very rare (<1/10.000 patients). Due to its rarity and the scarce cases reported, mesalazine-induced lung injury needs to be highly suspected in a patient with onset of respiratory symptoms and UC under treatment with salicylates. It should make the clinician formulate a differential diagnosis that includes not only infections (tuberculosis, bacterial...) or the inflammatory bowel disease itself, but also the current coronavirus disease 2019 (COVID‐19) since their clinical and radiological manifestations may be very similar.
Share Button
New comment
Comments
No comments for this article
References
1. Sicilia B, García-López S, González-Lama Y, et al, en representación del Grupo Español de Trabajo de Enfermedad de Crohn y Colitis Ulcerosa or Spanish Group for Working on Crohn’s Disease and Ulcerative Colitis (GETECCU). Guía GETECCU 2020 para el tratamiento de la colitis ulcerosa. Elaborada con metodología GRADE. Gastroenterol Hepatol. 2020;43(1):1-57.
2. Kotsiou OS, Gourgoulianis KI. A case report of mesalazine-induced lung injury: A reversible drug side effect. Respir Med Case Rep. 2019;27:100865. PMID: 31193970. DOI: 10.1016/j.rmcr.2019.100865
3. Kim JH, Lee JH, Koh ES, et al. Acute eosinophilic pneumonia related to a mesalazine suppository. Asia Pac Allergy. 2013;3(2):136-9.
4. Oi H, Suzuki A, Yamano Y, et al. Mesalazine-induced lung injury with severe respiratory failure successfully treated with steroids and non-invasive positive pressure ventilation. Respir Med Case Rep. 2020;31:101157.
5. Martí-Aguado D, Ballester MP, Mínguez M. Risk factors and management strategies associated with non-response to aminosalicylates as a maintenance treatment in ulcerative colitis. Rev Esp Enferm Dig. 2021;113(6):447-453.
Related articles

Letter

Tofacitinib-induced eosinophilia

DOI: 10.17235/reed.2023.9831/2023

Letter

Mesalazine-induced esophageal ulcers. A rare adverse effect

DOI: 10.17235/reed.2023.9723/2023

Letter

Perianal Paget’s disease

DOI: 10.17235/reed.2022.9304/2022

Letter

Chinese dragon sign of ulcerative colitis

DOI: 10.17235/reed.2022.9154/2022

Letter

Ulcerative colitis exacerbated by strongyloidiasis

DOI: 10.17235/reed.2022.9044/2022

Review

Clinical settings with tofacitinib in ulcerative colitis

DOI: 10.17235/reed.2022.8660/2022

Letter

The effect of Adacolumn® on ulcerative colitis with COVID-19

DOI: 10.17235/reed.2020.7156/2020

Letter

Sweet syndrome in severe ulcerative flare

DOI: 10.17235/reed.2020.6995/2020

Case Report

Effects of mesalazine enemas on lymphoid follicular proctitis

DOI: 10.17235/reed.2018.5481/2018

Case Report

Topical mesalazine as a cause of Stevens-Johnson syndrome

DOI: 10.17235/reed.2018.5429/2017

Letter to the Editor

Ulcerative colitis with gastric and duodenal involvement

DOI: 10.17235/reed.2017.4685/2016

Editorial

Specialist care in the management of inflammatory bowel disease

DOI: 10.17235/reed.2016.4628/2016

Original

Mercaptopurine and inflammatory bowel disease: the other thiopurine

DOI: 10.17235/reed.2016.4546/2016

Case Report

Mesalamine-induced myopericarditis - A case report

DOI: 10.17235/reed.2016.4016/2015

Citation tools
Aparicio Serrano A, Gallego Jiménez E, Castro Rodríguez J, Soto Escribano P, Iglesias Flores E, Marín Pedrosa S, et all. Mesalazine induced interstitial pneumonitis in the COVID era. 8635/2021


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 1192 visits.
This article has been downloaded 95 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 22/01/2022

Accepted: 01/02/2022

Online First: 18/02/2022

Published: 07/07/2022

Article Online First time: 27 days

Article editing time: 166 days


Share
This article has been rated by 1 readers.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology